Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
GNVC's Cash to Debt is ranked higher than
98% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. GNVC: No Debt )
GNVC' s 10-Year Cash to Debt Range
Min: 0.83   Max: No Debt
Current: No Debt

Equity to Asset 0.80
GNVC's Equity to Asset is ranked higher than
82% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GNVC: 0.80 )
GNVC' s 10-Year Equity to Asset Range
Min: 0.35   Max: 0.89
Current: 0.8

0.35
0.89
Interest Coverage No Debt
GNVC's Interest Coverage is ranked higher than
96% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GNVC: No Debt )
GNVC' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: -15.46
M-Score: -0.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -279.58
GNVC's Operating margin (%) is ranked higher than
62% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. GNVC: -279.58 )
GNVC' s 10-Year Operating margin (%) Range
Min: -466.81   Max: -14.73
Current: -279.58

-466.81
-14.73
Net-margin (%) -272.11
GNVC's Net-margin (%) is ranked higher than
62% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. GNVC: -272.11 )
GNVC' s 10-Year Net-margin (%) Range
Min: -432.31   Max: -11.32
Current: -272.11

-432.31
-11.32
ROE (%) -217.33
GNVC's ROE (%) is ranked higher than
51% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. GNVC: -217.33 )
GNVC' s 10-Year ROE (%) Range
Min: -240.47   Max: -16.08
Current: -217.33

-240.47
-16.08
ROA (%) -138.12
GNVC's ROA (%) is ranked higher than
50% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. GNVC: -138.12 )
GNVC' s 10-Year ROA (%) Range
Min: -138.12   Max: -6.7
Current: -138.12

-138.12
-6.7
ROC (Joel Greenblatt) (%) -2002.72
GNVC's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. GNVC: -2002.72 )
GNVC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2620.67   Max: -26.74
Current: -2002.72

-2620.67
-26.74
Revenue Growth (%) -40.10
GNVC's Revenue Growth (%) is ranked higher than
60% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. GNVC: -40.10 )
GNVC' s 10-Year Revenue Growth (%) Range
Min: -67   Max: 5.9
Current: -40.1

-67
5.9
EBITDA Growth (%) -7.30
GNVC's EBITDA Growth (%) is ranked higher than
76% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. GNVC: -7.30 )
GNVC' s 10-Year EBITDA Growth (%) Range
Min: -43.5   Max: 12.1
Current: -7.3

-43.5
12.1
EPS Growth (%) -7.40
GNVC's EPS Growth (%) is ranked higher than
79% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. GNVC: -7.40 )
GNVC' s 10-Year EPS Growth (%) Range
Min: -43.1   Max: 9.2
Current: -7.4

-43.1
9.2
» GNVC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

GNVC Guru Trades in Q4 2012

Jim Simons 10,900 sh (New)
» More
Q1 2013

GNVC Guru Trades in Q1 2013

Jim Simons 14,400 sh (+32.11%)
» More
Q2 2013

GNVC Guru Trades in Q2 2013

Jim Simons 22,500 sh (+56.25%)
» More
Q3 2013

GNVC Guru Trades in Q3 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GNVC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.60
GNVC's P/B is ranked higher than
85% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. GNVC: 2.60 )
GNVC' s 10-Year P/B Range
Min: 0.43   Max: 41.53
Current: 2.6

0.43
41.53
P/S 5.80
GNVC's P/S is ranked higher than
84% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. GNVC: 5.80 )
GNVC' s 10-Year P/S Range
Min: 0.63   Max: 22.91
Current: 5.8

0.63
22.91
EV-to-EBIT -2.66
GNVC's EV-to-EBIT is ranked higher than
65% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GNVC: -2.66 )
GNVC' s 10-Year EV-to-EBIT Range
Min: 24.6   Max: 63.3
Current: -2.66

24.6
63.3
Current Ratio 4.91
GNVC's Current Ratio is ranked higher than
76% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. GNVC: 4.91 )
GNVC' s 10-Year Current Ratio Range
Min: 1.46   Max: 8.55
Current: 4.91

1.46
8.55
Quick Ratio 4.91
GNVC's Quick Ratio is ranked higher than
78% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. GNVC: 4.91 )
GNVC' s 10-Year Quick Ratio Range
Min: 1.46   Max: 8.55
Current: 4.91

1.46
8.55

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.00
GNVC's Price/Net Cash is ranked higher than
94% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. GNVC: 3.00 )
GNVC' s 10-Year Price/Net Cash Range
Min: 0.9   Max: 34.6
Current: 3

0.9
34.6
Price/Net Current Asset Value 2.60
GNVC's Price/Net Current Asset Value is ranked higher than
95% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. GNVC: 2.60 )
GNVC' s 10-Year Price/Net Current Asset Value Range
Min: 0.82   Max: 28.94
Current: 2.6

0.82
28.94
Price/Tangible Book 2.40
GNVC's Price/Tangible Book is ranked higher than
89% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. GNVC: 2.40 )
GNVC' s 10-Year Price/Tangible Book Range
Min: 0.59   Max: 16.67
Current: 2.4

0.59
16.67
Price/Median PS Value 1.20
GNVC's Price/Median PS Value is ranked higher than
78% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. GNVC: 1.20 )
GNVC' s 10-Year Price/Median PS Value Range
Min: 0.17   Max: 4.06
Current: 1.2

0.17
4.06
Earnings Yield (Greenblatt) 374.70
GNVC's Earnings Yield (Greenblatt) is ranked higher than
98% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. GNVC: 374.70 )
GNVC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 18153.8
Current: 374.7

0
18153.8
Forward Rate of Return (Yacktman) -69.86
GNVC's Forward Rate of Return (Yacktman) is ranked higher than
58% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. GNVC: -69.86 )
GNVC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -58.2   Max: -43
Current: -69.86

-58.2
-43

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GVC1.Germany
Genvec, Inc. was incorporated in Delaware in 1992. Genvec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease (FMD). In the collaboration with Novartis, the Company's hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. In addition to its therapeutic product development programs, the Company is working with collaborators to develop vaccines using its adenovector technology. The Company is currently developing preventative vaccines, including RSV, HSV, dengue fever, and malaria. The Company is developing vaccines against RSV, the single most important viral cause of lower respiratory infections in infants and young children. It is developing vaccines for the prevention and treatment of HSV including HSV type 2 (HSV-2) the virus responsible for most cases of genital herpes. With its collaborators, the Company is generating vaccine candidates for the prevention of dengue fever. Dengue fever is a viral disease spread by mosquitoes that historically affected 50 million to 100 million people each year. With its collaborators the Company is generating vaccine candidates for the prevention of malaria. With its collaborators, the Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks. FMD is a highly contagious viral disease affecting cows and other animals with cloven hooves. The Company currently has two suppliers for its clinical manufacturing components, one for human health and one for animal health candidates. Currently it procures raw materials, including specialized components known as resins, for its product purification and testing methods from a limited number of suppliers. The Company faces intense competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad. The research, development, testing, manufacture, quality, safety, effectiveness, labeling, packaging, storage, approval, distribution, marketing, advertising, and promotion of any biologic products developed by the Company or its collaborators are subject to regulation by federal, state, local, and foreign governmental authorities.
» More Articles for GNVC

Headlines

Articles On GuruFocus.com
GenVec Inc. Reports Operating Results (10-K) Mar 11 2011 
GenVec Inc. Reports Operating Results (10-Q) May 07 2010 
GenVec Inc. Reports Operating Results (10-Q) Nov 06 2009 
GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants Aug 27 2009 
GenVec Inc. Reports Operating Results (10-Q) Aug 07 2009 
GenVec Inc. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
Nasdaq stocks posting largest volume increases Jul 31 2014
GENVEC INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements... Jun 16 2014
GENVEC INC Financials May 16 2014
U.S./Canada daily earnings hits & misses May 12 - 1710 ET May 12 2014
GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 12 2014
GenVec sees FY14 cash burn between $5M-$7M May 12 2014
GenVec reports Q1 EPS (7c), one estimate 4c May 12 2014
GenVec Reports First Quarter 2014 Financial Results May 12 2014
GenVec's CEO Discusses Q4 2013 Results - Earnings Call Transcript Mar 28 2014
GenVec Reports Fourth Quarter and 2013 Year-End Financial Results Mar 28 2014
GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 28 2014
GenVec Reports Fourth Quarter and 2013 Year-End Financial Results Mar 28 2014
Why GenVec (GNVC) Stock Is Up In Aftermarket Trading Mar 27 2014
GenVec To Release Fourth Quarter And Year-End 2013 Financial Results And Conduct A Conference Call... Mar 21 2014
GenVec To Release Fourth Quarter And Year-End 2013 Financial Results And Conduct A Conference Call... Mar 21 2014
GENVEC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Mar 18 2014
GenVec Announces $9 Million Registered Direct Offering Mar 13 2014
GenVec Announces $9 Million Registered Direct Offering Mar 13 2014
GenVec to Present at 26th Annual ROTH Conference Mar 03 2014
GenVec to Present at 26th Annual ROTH Conference Mar 03 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide